Morgan Stanley
ZOM

Morgan Stanley’s Zomedica Corp. ZOM Stock Holding History

Morgan Stanley’s Portfolio ZOM Stock Details ZOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-193,828
Closed -$23.3K – 8348
2024
Q4 		$23.3K Buy
193,828
+350
+0.2% +$44 ﹤0.01% 6519
2024
Q3 		$26.5K Sell
193,478
-4,300
-2% -$603 ﹤0.01% 6412
2024
Q2 		$28.9K Buy
197,778
+3,000
+2% +$449 ﹤0.01% 6343
2024
Q1 		$28.4K Sell
194,778
-194,778
-50% -$27.2K ﹤0.01% 6390
2023
Q4 		$78K Buy
389,556
+184,778
+90% +$32.5K ﹤0.01% 6240
2023
Q3 		$34.2K Sell
204,778
-35,915
-15% -$6.97K ﹤0.01% 6316
2023
Q2 		$48.1K Buy
240,693
+215
+0.1% +$44 ﹤0.01% 6228
2023
Q1 		$50.9K Sell
240,478
-195,312
-45% -$47.9K ﹤0.01% 6290
2022
Q4 		$71K Buy
435,790
+154,222
+55% +$31.6K ﹤0.01% 6132
2022
Q3 		$59K Sell
281,568
-280,009
-50% -$74.1K ﹤0.01% 6339
2022
Q2 		$124K Sell
561,577
-50,388
-8% -$12.8K ﹤0.01% 6162
2022
Q1 		$206K Sell
611,965
-20,550
-3% -$6.72K ﹤0.01% 5914
2021
Q4 		$193K Sell
632,515
-47,982
-7% -$21.6K ﹤0.01% 6094
2021
Q3 		$356K Sell
680,497
-1,310,393
-66% -$773K ﹤0.01% 5690
2021
Q2 		$1.66M Buy
1,990,890
+1,977,070
+14,306% +$1.84M ﹤0.01% 4775
2021
Q1 		$22K Sell
13,820
-89,294
-87% -$146K ﹤0.01% 6697
2020
Q4 		$24K Buy
103,114
+81,509
+377% +$10.4K ﹤0.01% 6385
2020
Q3 		$2K Buy
+21,605
New +$2.98K ﹤0.01% 6629
2020
Q2 		– Sell
-100
Closed – – 6833
2020
Q1 		$0 Sell
100
-39
-28% -$9 ﹤0.01% 6839
2019
Q4 		$0 Sell
139
-135
-49% -$45 ﹤0.01% 6869
2019
Q3 		$0 Sell
274
-111,324
-100% -$34.5K ﹤0.01% 6868
2019
Q2 		$25K Buy
111,598
+104,723
+1,523% +$31.7K ﹤0.01% 5863
2019
Q1 		$2K Sell
6,875
-75,509
-92% -$66.6K ﹤0.01% 6488
2018
Q4 		$102K Sell
82,384
-530
-0.6% -$840 ﹤0.01% 5553
2018
Q3 		$155K Sell
82,914
-4,726
-5% -$10.1K ﹤0.01% 5552
2018
Q2 		$197K Buy
87,640
+87,540
+87,540% +$176K ﹤0.01% 5540
2018
Q1 		$0 Hold
100
– – ﹤0.01% 6774
2017
Q4 		$0 Buy
+100
New +$222 ﹤0.01% 6722

Other funds holding ZOM

AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
OPS
Orion Portfolio Solutions Omaha, Nebraska $10.2B AUM 6.73% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
SWM
Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
PRTG
Post Resch Tallon Group Pittsford, New York $145M AUM 25.19% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
GJIA
Glass Jacobson Investment Advisors Owings Mills, Maryland $290M AUM 17.7% 1-Year Est. Return
PCIA
Prime Capital Investment Advisors Overland Park, Kansas $8.65B AUM 19.52% 1-Year Est. Return

Morgan Stanley's ZOM Position: Q1 2025 in Review

Morgan Stanley sold out of Zomedica Corp. (ZOM) in Q1 2025, closing a stake of 193,828 shares — an estimated $23.3K sold.

Morgan Stanley first reported a position in ZOM in Q4 2017 and held it in 28 quarters. The position peaked at $1.66M in Q2 2021. 23 funds tracked by Wall St. Rank hold ZOM as of Q1 2025.

  • Morgan Stanley reported no remaining Zomedica Corp. position as of Q1 2025 after selling out during the quarter.
  • Morgan Stanley sold 193,828 Zomedica Corp. shares in Q1 2025, an estimated $23.3K.
  • Morgan Stanley first reported a position in Zomedica Corp. in Q4 2017 and held it in 28 quarters.
  • Morgan Stanley's Zomedica Corp. position peaked at $1.66M in Q2 2021.
  • 23 funds tracked by Wall St. Rank held Zomedica Corp. as of Q1 2025.

Based on Morgan Stanley's 13F filing for Q1 2025, filed 15 May 2025.